Bioanalytical Assays of AAV Therapeutics: Recent Advances and Considerations


Tom Zhang, PHD. | Mike Mencer | Niancao Chen

Over the last decade, the advance of manufacture, delivery and immunity modulation, gene therapeutics (GTs) has resurged as most popular modalities. Due to its special nature in delivery and biodistribution as well as the unique mechanism of actions, conventional bioanalytical approaches have limitations in supporting the development of GTs. This review summaries the challenges and considerations in designing GTs related bioassays.

Your form has been successfully submitted! Click the button below to access.
READ MORE
Tom Zhang, PHD.
MEET THE AUTHOR

Tom Zhang, PHD.

Chief Scientific Officer, Large Molecule Bioanalysis
LEARN MORE
Mike Mencer
MEET THE AUTHOR

Mike Mencer

Executive Vice President and General Manager, Early Phase
LEARN MORE

RELATED CONTENT